妇科肿瘤临床试验:过去、现在与未来
妇科肿瘤组历史上开展了改变实践的临床试验,奠定了卵巢癌、子宫内膜癌、宫颈癌和滋养细胞肿瘤的初始治疗标准。试验设计格局已明显转向精简药物开发、聚焦特定患者人群,转化科学可加速新疗法引入,需采用更智能的试验设计以快速将正确药物用于正确患者。
要点
- 妇科肿瘤组的历史试验确立了铂类联合紫杉类化疗为卵巢癌标准方案。
- GOG-0240 为晚期宫颈癌化疗联合贝伐珠单抗提供证据。
- 试验设计已转向精简药物开发、聚焦特定患者人群和适应证。
核心结论
- 必须纳入更智能的临床试验设计,以快速将正确药物用于正确患者,持续改善妇科癌症女性结局。
研究设计与样本
- 本文为妇科肿瘤临床试验过去、现在与未来的综述,未报告检索范围与样本量。
主要发现
- GOG-0111 试验确立了卵巢癌铂类联合紫杉类化疗的标准。
- GOG-0240 试验为晚期宫颈癌化疗加用贝伐珠单抗提供证据。
- 近几十年试验设计格局明显改变,强调精简药物开发、聚焦特定患者人群和研究药物的适应证。
关键数值与推荐
- GOG-0111 试验设定卵巢癌铂类联合紫杉类化疗标准。
- GOG-0240 试验提供晚期宫颈癌化疗加用贝伐珠单抗的证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Gynecologic Oncology Group has historically performed ground-breaking, practice-changing clinical trials in women's cancers. The current standard of care for initial treatment of ovarian, endometrial, cervical, and trophoblastic cancers was determined by clinical trials completed within this cooperative group structure. For example, trial GOG-0111 set the standard for combining platinum and taxane chemotherapy in ovarian cancer, and more recently GOG-0240 provided evidence for adding bevacizumab to chemotherapy for women with advanced cervical cancer. The landscape of clinical trial design has markedly changed in recent decades, with a clear emphasis on streamlining drug development towards specific patient populations and indications for investigational agents. Translational science in gynecologic cancers can set the stage for rapid and efficient introduction of new therapies for our patients. The gynecologic oncology community of researchers and clinicians is well positioned to enter into the new era of drug development, with breakthrough discoveries increasing each year. It is clear that we must incorporate smarter clinical trial design to get the right drugs to the right patients expeditiously, so we can continue to improve outcome for women with gynecologic cancers.
引用
- Annunziata CM, Kohn EC. Clinical trials in gynecologic oncology: Past, present, and future. Gynecol Oncol. 2017. PMID: 29212614. doi:10.1016/j.ygyno.2017.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。